News

LungFit PH, a device developed by Beyond Air for administering nitric oxide (NO) therapy, has received marketing approval from the Australian Therapeutic Goods Administration (TGA), which will allow the company to market the device as a Class IIb medical device. NO causes blood vessels to relax and widen, lowering…

An imaging technique called 18F-FAPI PET may be able to detect the earliest signs of changes in blood vessel tissues that occur in pulmonary arterial hypertension (PAH), a new study reports. According to researchers, this novel approach, which uses positron emission tomography or PET imaging, may help…

People with pulmonary arterial hypertension (PAH) seen to be at an intermediate risk of death — whether in the low or high range of that middle-level risk — were more likely to have better outcomes when treated with Adempas (riociguat) than given a placebo in a Phase 3…

The dosing regimen for Winrevair (sotatercept-csrk) is optimal for balancing efficacy and safety in adults with pulmonary arterial hypertension (PAH), an analysis of clinical trial data shows. This regimen is “well-justified based on the totality of the observed safety and efficacy data from Phase 2 and Phase 3…

Discontinuing antidepressants during pregnancy might reduce the risk of persistent pulmonary hypertension of the newborn (PPHN) and hospitalization, a Danish study suggests. “However, the reduced risk for newborns should be considered in light of the potential risks associated with untreated maternal depression, which may affect both the mother and…

Body weight-adjusted Uptravi (selexipag) dosing for children and adolescents with pulmonary arterial hypertension (PAH) resulted in exposure to the treatment’s active ingredient comparable to that in adults with PAH, a study showed. The study assessed the treatment’s pharmacokinetics — its…

The U.S. Food and Drug Administration (FDA) has provided Tiakis Biotech with advice for a planned Phase 2 clinical trial testing tiprelestat for pulmonary arterial hypertension (PAH). The ATHENA trial, which will assess the treatment’s safety and efficacy, is expected to enroll 90 patients, randomly assigned to receive…

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to ALG-801, Alivegen’s experimental treatment for pulmonary arterial hypertension (PAH). That designation aims to support the development of therapies for rare diseases, or those affecting fewer than 200,000 people in the U.S. It comes with certain…

Cereno Scientific said it has enrolled nine additional people with pulmonary arterial hypertension (PAH) in its expanded access program (EAP) for investigational therapy CS1, bringing the total number of patients in the program to 10. The patients will continue receiving CS1 after completing a Phase 2a clinical trial.

People with pulmonary arterial hypertension (PAH) and their physicians hardly ever agree on the severity of symptoms, a study in the U.S., Europe and Japan reveals. Symptom discordance was more likely when PAH was more severe and was associated with worse health-related quality of life (HRQoL). “Physicians consistently under-recognized the…

Using in-depth analyses and machine learning, scientists have identified several molecules and genes involved in metabolism that may be diagnostic markers of pulmonary arterial hypertension (PAH). Specifically, their research found five small molecules, or metabolites, and three metabolism-related genes that are tied to a PAH diagnosis. All were “identified…

An oxygen-sensing protein called hypoxia-inducible factor-1alpha, or HIF-1alpha, may contribute to worsening pulmonary arterial hypertension (PAH) and is a possible therapeutic target for people with this rare type of pulmonary hypertension, a study by Chinese scientists found. According to the researchers, HIF-1alpha may worsen PAH by increasing the uptake…